YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

Rhea-AI Summary

YS Biopharma to report first nine months of fiscal year 2024 financial results on April 19, 2024

GAITHERSBURG, Md., April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it plans to release its financial results for the first nine months of the fiscal year ended March 31, 2024, before the U.S. market opens on Friday, April 19, 2024.

The Company's management will hold an earnings conference call at 8:00 A.M. Eastern Time on Friday, April 19, 2024 to discuss the financial results. Listeners may access the call by dialing the following numbers:

United States Toll Free:	1-888-346-8982
International:	1-412-902-4272
Mainland China Toll Free:	4001-201203
Canada Toll Free:	1-855-669-9657
Hong Kong:	852-301-84992

Upon dialing-in, participants should ask to be joined into the YS Biopharma Co., Ltd. call.

The replay will be accessible through April 26, 2024 by dialing the following numbers:

United States Toll Free:	1-877-344-7529
International:	1-412-317-0088
Canada Toll Free:	1-855-669-9658
Access Code:	2468327

A live and archived webcast of the conference call will also be available at the Company's investor relations website at https://investor.ysbiopharm.com/.

About YS Biopharma 

YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit www.ysbiopharma.com.

Investor Relations Contact

Alyssa Li
Director of Investor Relations
Email: ir@yishengbio.com 

Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-to-report-first-nine-months-of-fiscal-year-2024-financial-results-on-april-19-2024-302118047.html

SOURCE YS Biopharma Co., Ltd.

FAQ

When will YS Biopharma report its financial results for the first nine months of fiscal year 2024?

YS Biopharma will report its financial results on April 19, 2024.

What time will the earnings conference call be held on April 19, 2024?

The earnings conference call will be held at 8:00 A.M. Eastern Time on April 19, 2024.

How can listeners access the earnings conference call?

Listeners can access the call by dialing the provided numbers based on their location.

Until when will the replay of the conference call be accessible?

The replay will be accessible through April 26, 2024.

Where can a live and archived webcast of the conference call be found?

A live and archived webcast will be available at the Company's investor relations website at https://investor.ysbiopharm.com/.